Harbor Multi-Asset Explorer ETF (MAPP)
- Previous Close
20.86 - Open
21.23 - Bid 21.40 x 900
- Ask 21.47 x 900
- Day's Range
21.31 - 21.31 - 52 Week Range
18.90 - 21.81 - Volume
20 - Avg. Volume
207 - Net Assets 3.8M
- NAV 21.40
- PE Ratio (TTM) --
- Yield --
- YTD Daily Total Return 5.18%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.92%
To seek to achieve the fund’s investment objective, Harbor Capital Advisors Inc., the fund’s investment adviser (the “advisor”), allocates the fund’s assets among various asset classes and market sectors based on its assessment of global economic and market conditions, primarily through investments in a diversified portfolio of exchange-traded funds, including other funds managed by the advisor.
Harbor
Fund Family
Global Allocation
Fund Category
3.8M
Net Assets
2023-09-13
Inception Date
Performance Overview: MAPP
Trailing returns as of 4/26/2024. Category is Global Allocation.
People Also Watch
Holdings: MAPP
Top 10 Holdings (82.65% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: MAPP
IRWD: Raising target price to $9.00
IRONWOOD PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetJAZZ: Raising target price to $115.00
JAZZ PHARMACEUTICALS PLC has an Investment Rating of HOLD; a target price of $115.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetJAZZ: Lowering target price to $114.00
JAZZ PHARMACEUTICALS PLC has an Investment Rating of HOLD; a target price of $114.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetIRWD: Lowering target price to $8.00
IRONWOOD PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target